



Statement of stand-alone Financial Results for the quarter and year ended 31st March, 2012

Rs. lakhs

PARTICULARS (REFER NOTES BELOW)	THREE MONTHS ENDED			YEAR ENDED (AUDITED)	
	31-MAR-2012	31-DEC- 2011	31-MAR-2011	31-MAR-2012	31-MAR-2011
01. Net Sales / Income from Operations (including Excise Duty & Sales Tax)	11839	11240	8744	43042	33826
02. Other Operating Income	1225	947	895	3721	3348
03. TOTAL INCOME FROM OPERATIONS	13064	12187	9639	46763	37174
04. EXPENDITURE					
a) Cost of materials consumed	3413	2686	2439	11768	9742
b) Purchases of stock-in-trade	330	293	636	1553	1672
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-42	252	-456	75	-1148
d) Employee benefits expense	1814	1706	1224	6487	5112
e) Depreciation and amortization expense	378	406	408	1541	1435
f) Other Expenses	4577	4021	3651	15119	12616
TOTAL EXPENSES	10470	9364	7902	36543	29429
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	2594	2823	1737	10220	7745
06. Other Income	74	24	-15	327	72
07. Finance costs	609	561	312	2296	1419
08. Profit / (Loss) from ordinary activities before tax	2059	2286	1410	8251	6398
09. Tax expense, including deferred tax	606	504	-46	2038	1186
10. Net Profit / Loss (-) from ordinary activities after tax	1453	1782	1456	6213	5212
11. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3115	3115	2815	3115	2815
12. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year				43632	31876
13. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.)	5.00 5.00	6.19 6.19	5.17 5.17	21.39 21.39	18.52 18.52
14. Public Shareholding:					
a) Number of Shares	13,378,081	13,389,871	10,459,455	13,378,081	10,459,455
b) Percentage of Shareholding	42.95	42.99	37.16	42.95	37.16
15. Promoters and Promoter Group Shareholding					
a) Pledged / Encumbered – No. of shares	-	-	1,050,000	-	1,050,000
Percentage (as a % of the total shareholding of promoter and promoter group)	-	-	5.94	-	5.94
Percentage (as a % of the total share capital of the company)	-	-	3.73	-	3.73
b) Non – encumbered – No. of shares	17,769,881	17,758,081	16,638,497	17,769,881	16,638,497
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	94.06	100.00	94.06
Percentage (as a % of the total share capital of the company)	57.05	57.01	59.11	57.05	59.11

The above financial results were reviewed / audited by the statutory auditors of the Company, the Audit Committee and approved by the Board of Directors at a meeting held at Hyderabad, on Monday, the 28th May, 2012. The net sales /income from operations include sales tax of (Rs. lakhs) 304, 311, 213, 1123, 854 and excise duty of (Rs. lakhs) 82, 107, 115, 307, 264 and other operating income includes excise rebate of (Rs. Lakhs) 129, 155, 182, 656, 550 respectively for the quarters ended on 31st March, 2012, 31st December, 2011, and 31st March, 2011. and for the year ended on 31st March, 2012 and 2011. There are no exceptional and extraordinary items to be reported for the period under review. Figures for the quarter ended on 31st March are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the financial year.. In respect of reference relating to non-accounting of minimum alternate tax credit, in the Auditors' Report, the company will review the position during the current financial year.

Dated at Hyderabad, this, the 28th day of May, 2012.
for and on behalf of the Board of Directors,
NATCO Pharma Limited

Dr. P. Bhaskara Narayana
Director & Chief Financial Officer

Status of Investor Complaints as at 31st March, 2012

Pending as on 01-10-2012	Nil
Received during the quarter	49
Resolved during the quarter	49
Pending as on 31-03-2012	Nil



Stand-alone Statement of Assets and Liabilities (Rs. in lakhs)

Particulars	As at 31-Mar-2012	As at 31-Mar-2011
Equity & Liabilities		
Shareholders' Funds		
a) Share Capital	3115	2815
b) Reserves & Surplus	43632	31876
c) Money received against share warrants	-	-
Sub-total : Shareholders' funds	46747	34691
Share application money pending allotment	-	-
Non-current liabilities		
a) Long term borrowings	13887	12418
b) Deferred tax liabilities (net)	2889	2509
c) Other long-term liabilities	135	125
d) Long term provisions	978	867
Sub-total : Non-current Liabilities	17889	15919
Current Liabilities		
a) Short term borrowings	8100	7202
b) Trade payables	10199	8097
c) Other current liabilities	7422	3918
d) Short-term provisions	24	12
Sub-total : Current Liabilities	25745	19229
TOTAL – EQUITY AND LIABILITIES	90381	69839
Assets		
Non-current Assets		
a) Fixed Assets	47387	34093
b) Non-current investments	7583	7037
c) Deferred tax assets (net)	-	-
d) Long term loans and advances	5582	4384
e) Other non-current assets	42	96
Sub-toital : Non-current Assets	60594	45610
Current Assets		
a) Current Investments	74	82
b) Inventories	9728	9302
c) Trade receivables	9334	7037
d) Cash and cash equivalents	2995	3097
e) Short term loans and advances	7542	4700
f) Other current assets	114	11
Sub-total : Current Assets	29787	24229
TOTAL – ASSETS	90381	69839



Statement of consolidated Financial Results for the quarter and year ended 31st March, 2012

Rs. lakhs

PARTICULARS (REFER NOTES BELOW)	THREE MONTHS ENDED (UNREVIEWED/UNAUDITED)			YEAR ENDED (AUDITED)	
	31-MAR-2012	31-DEC- 2011	31-MAR-2011	31-MAR-2012	31-MAR-2011
01. Net Sales / Income from Operations (including Excise Duty & Sales Tax)	14166	13596	10628	51845	44943
02. Other Operating Income	1218	947	902	3713	3364
03. TOTAL INCOME FROM OPERATIONS	15384	14543	11530	55558	48307
04. EXPENDITURE					
a) Cost of materials consumed	5372	4617	3747	18660	18276
b) Purchases of stock-in-trade	330	293	636	1553	1672
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-42	252	-456	75	-1148
d) Employee benefits expense	2176	2049	1553	7777	6407
e) Depreciation and amortization expense	166	408	401	1583	1474
f) Other Expenses	4965	4217	3828	15944	13657
TOTAL EXPENSES	12967	11836	9709	45592	40338
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	2417	2707	1821	9966	7969
06. Other Income	74	35	45	350	135
07. Finance costs	621	581	401	2362	1576
08. Profit / (Loss) from ordinary activities before tax	1870	2161	1465	7954	6528
09. Tax expense, including deferred tax	619	504	42	2107	1321
10. Minority Interest	-14	-43	-15	-114	-144
11. Net Profit / Loss (-) from ordinary activities after tax	1265	1700	1438	5961	5351
12. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3115	3115	2815	3115	2815
13. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year				44086	32429
14. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.)	4.35 4.35	5.91 5.91	5.11 5.11	20.53 20.53	19.01 19.01
15. Public Shareholding:					
a) Number of Shares	13,378,081	13,389,871	10,459,455	13,378,081	10,459,455
b) Percentage of Shareholding	42.95	42.99	37.16	42.95	37.16
16. Promoters and Promoter Group Shareholding					
a) Pledged / Encumbered – No. of shares	-	-	1,050,000	-	1,050,000
Percentage (as a % of the total shareholding of promoter and promoter group)	-	-	5.94	-	5.94
Percentage (as a % of the total share capital of the company)	-	-	3.73	-	3.73
b) Non – encumbered – No. of shares					
Percentage (as a % of the total shareholding of promoter and promoter group)	17,769,881 100.00	17,758,081 100.00	16,638,497 94.06	17,769,881 100.00	16,638,497 94.06
Percentage (as a % of the total share capital of the company)	57.05	57.01	59.11	57.05	59.11

The above financial results were reviewed / audited by the statutory auditors of the Company, the Audit Committee and approved by the Board of Directors at a meeting held at Hyderabad, on Monday, the 28th May, 2012. The net sales /income from operations include sales tax of (Rs. lakhs) 304, 311, 213, 1123, 854 and excise duty of (Rs. lakhs) 82, 107, 115, 307, 264 and other operating income includes excise rebate of (Rs. Lakhs) 129, 155, 182, 656, 550 respectively for the quarters ended on 31st March, 2012, 31st December, 2011, and 31st March, 2011. and for the year ended on 31st March, 2012 and 2011. There are no exceptional and extraordinary items to be reported for the period under review. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. Figures for the quarter ended on 31st March are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the financial year. The stand-alone results are available on the company's web-site www.natcopharma.co.in. In respect of reference relating to non-accounting of minimum alternate tax credit, in the Auditors' Report, the company will review the position during the current financial year.

Dated at Hyderabad, this, the 28th day of May, 2012.
for and on behalf of the Board of Directors,
NATCO Pharma Limited


Dr. P. Bhaskara Narayanan
Director & Chief Financial Officer

Status of Investor Complaints as at 31st March, 2012

Pending as on 01-10-2012	Nil
Received during the quarter	49
Resolved during the quarter	49
Pending as on 31-03-2012	Nil



Consolidated Statement of Assets and Liabilities (Rs. in lakhs)

Particulars	As at 31-Mar-2012	As at 31-Mar-2011
Equity & Liabilities		
Shareholders' Funds		
a) Share Capital	3115	2815
b) Reserves & Surplus	44086	32429
c) Money received against share warrants	-	-
Sub-total : Shareholders' funds	47201	35244
Share application money pending allotment	-	-
Minority Interest	88	106
Non-current liabilities		
a) Long term borrowings	13979	12427
b) Deferred tax liabilities (net)	2889	2509
c) Other long-term liabilities	135	125
d) Long term provisions	978	1002
Sub-total : Non-current Liabilities	17981	16063
Current Liabilities		
a) Short term borrowings	8100	7202
b) Trade payables	10957	9494
c) Other current liabilities	7429	3930
d) Short-term provisions	66	12
Sub-total : Current Liabilities	26552	20638
TOTAL – EQUITY AND LIABILITIES	91822	72051
Assets		
Non-current Assets		
a) Fixed Assets	49026	35694
b) Goodwill on consolidation	-	-
c) Non-current investments	6179	6179
d) Deferred tax assets (net)	-	-
e) Long term loans and advances	4627	4384
f) Other non-current assets	42	96
Sub-toital : Non-current Assets	59874	46353
Current Assets		
a) Current Investments	74	82
b) Inventories	11039	10223
c) Trade receivables	9469	7098
d) Cash and cash equivalents	3288	3237
e) Short term loans and advances	7965	5047
f) Other current assets	113	11
Sub-total : Current Assets	31948	25698
TOTAL – ASSETS	91822	72051



Report of segment wise revenue, Results and Capital Employed, (Un-audited) under Clause 41 of the Listing Agreement, for the quarter and year ended on 31st March, 2012

Rs. lakhs

	THREE MONTHS ENDED			YEAR TO DATE FIGURES FOR THE PERIOD ENDED	
	31-MAR-2012	31-DEC-2011	31-MAR-2011	31-MAR-2012	31-MAR-2011
01. Segment Revenue (Net Sales / Income (including Excise Duty & Sales Tax))					
a) Bulk Chemicals	3637	4298	3412	16318	12012
b) Formulations	8424	7546	5566	28244	23211
c) Job Work	205	228	300	896	1098
d) Unallocated (Others)	1094	743	610	3153	2203
Total	13360	12817	9888	48611	38524
Less : Inter-segment Revenue	221	608	249	1521	1350
Net Sales / Income from Operations	13139	12208	9639	47090	37174
02. Segment Results : Profit (+)/Loss (-) before tax and interest					
a) Bulk Chemicals	520	703	300	2943	1458
b) Formulations	1805	2872	2239	9688	11001
c) Job Work	169	186	202	727	872
d) Unallocated (Others)	1094	743	610	1983	-5513
Total	3588	4504	3351	15341	7818
Less : a) Interest	609	562	312	2296	1420
b) Oher allocable expenditure net of unallocable income	920	1656	1629	4792	-
Total Profit Before Tax	2059	2286	1410	8252	6398
03. Capital Employed (Segment Assets - Segment Liabilities)					
a) Bulk Chemicals	26619	26240	11242	26619	11242
b) Formulations	29356	27546	20847	29356	20847
c) Job Work	230	184	-	230	-
e) Unallocated (Others)	12321	-7576	2115	12321	2115
Total	68526	46394	34204	68526	34204

The above report of segment wise revenue, results and capital employed for the quarter and year ended on 31st March, 2012 was considered and taken on record by the Board of Directors at a meeting held at Hyderabad on Monday, the 28th May, 2012. Figures for the quarter ended on 31st March are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the financial year.

Dated at Hyderabad, this, the 28th day of May, 2012.

for and on behalf of the Board of Directors,

NATCO Pharma Limited

Dr. P. Bhaskara Narayana

Director & Chief Financial Officer

Regd. Office: **NATCO** House, Road # 2, Banjara Hills, **Hyderabad : 500 033.**